Dr. Marty Makary resigned as FDA Commissioner on May 12, 2026, after a 13-month tenure defined by mass layoffs, internal friction, and repeated clashes with HHS Secretary Robert Kennedy Jr. over drug policy decisions. He is the fourth high-profile departure from the Trump administration this year. Kyle Diamantas — the FDA's top food regulator and a lawyer without a medical degree — was named acting commissioner.

Career FDA officials told CBS News there was "widespread joy and relief" inside the agency at Makary's departure, with one senior official describing his tenure as marked by "endless self-promotion" and unprecedented micromanagement. Staff frequently learned about new FDA initiatives through press releases or medical journal articles rather than internal communication — a dysfunctional dynamic that compounded the damage from workforce reductions.

What Pushed Makary Out

The immediate trigger was the FDA's authorization of fruit-flavored vaping products. Makary opposed the decision and chose to resign rather than testify before Congress defending a regulatory position he didn't support. But the friction ran deeper than one ruling.

HHS Secretary RFK Jr. had already directed the firing of approximately 3,500 FDA workers — roughly 20% of the agency's total workforce — before Makary resigned. The resulting loss of scientific expertise threw drug review timelines, rare-disease approvals, and inspection programs into turmoil. Makary reportedly clashed with HHS leadership over rare-disease drug reviews and abortion pill policy throughout his tenure, with the flavored vape authorization being the breaking point that made departure preferable to continued internal conflict.

The departures represent a pattern: when FDA commissioners disagree with HHS leadership on regulatory decisions, they resign rather than issue guidance they oppose. This creates regulatory whiplash for manufacturers, healthcare providers, and clinicians who depend on predictable FDA decision-making.

What This Means for Nurses

The FDA's primary role intersects with nursing through drug approvals, device clearances, and the agency's oversight of medical products nurses use daily. The specific implications of this leadership transition:

  • Drug approval timelines: With 20% of the FDA's scientific staff gone and an acting commissioner who is a lawyer rather than a clinician, rare-disease approvals and expedited review processes could slow significantly. That affects nurses whose patients are on newer agents, in clinical trials, or awaiting approvals for orphan drugs.
  • Abortion medication policy: Makary's tenure saw ongoing battles over mifepristone access, including a Fifth Circuit ruling that Justice Alito temporarily stayed on May 14. Acting leadership's posture on reproductive healthcare drug policy is unclear. L&D and women's health nurses should monitor guidance updates closely.
  • Device oversight: FDA oversight of connected medical devices, infusion pumps, EHR-integrated tools, and AI-driven clinical decision support systems is relevant to every ICU, acute care, and home health nurse. Leadership instability at the FDA tends to slow proactive regulatory action on device safety and emerging technology oversight.
  • Inspection capacity: Manufacturing facility inspections and drug shortage monitoring have already been strained by workforce reductions. Nurses dealing with drug shortages — already a chronic problem in critical care — may see those conditions worsen if inspection and quality oversight capacity remains below pre-2025 levels.

The Larger Federal Health Policy Context

Makary's resignation is one data point in a broader pattern of disruption at federal health agencies in 2025–2026. The CDC, NIH, HRSA, and FDA have all seen significant leadership and staffing changes. For nurses, the practical effects include: more uncertainty about regulatory guidance timelines, fewer resources for nursing workforce programs (HRSA's Title VIII funding remains under pressure), and a federal health apparatus operating with substantially fewer subject-matter experts than it had 18 months ago.

What doesn't change regardless of FDA leadership: state nursing boards, state Medicaid regulations, and The Joint Commission accreditation remain the day-to-day regulatory framework for most bedside nurses. Federal drug oversight matters most for pharmacology updates, new agent approvals, and device safety notices. Track those through your facility's pharmacy department and clinical informatics channels — not FDA press releases, which have become inconsistent under recent leadership transitions.

For nurses in policy-facing roles (clinical informatics, quality, executive leadership), the FDA leadership vacuum is worth monitoring. The agency's capacity to respond quickly to emerging drug safety signals, device recalls, and new-agent approvals is directly tied to staffing and leadership stability — both of which are currently impaired.